Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study

Figure 1 Kaplan–Meier survival analysis after propensity score matching. A: Moderately differentiated gastric cancer (GC) patients 3 years postoperatively log odds of positive lymph nodes (LODDS) 1 vs LODDS2; B: Moderately differentiated GC patients 3 years postoperatively N1 + N2 vs N3a + N3b; C: Moderately differentiated GC patients 3-5 years postoperatively LODDS1 vs LODDS2; D: Moderately differentiated GC patients 3-5 years postoperatively N1 + N2 vs N3a + N3b; E: Poorly differentiated GC patients 3 years postoperatively LODDS1 vs LODDS2; F: Poorly differentiated GC patients 3 years after surgery N1 + N2 vs N3a + N3b; G: Poorly differentiated GC patients 3-5 years after surgery LODDS1 vs LODDS2; H: Poorly differentiated GC patients 3-5 years after surgery N1 + N2 vs N3a + N3b. LODDS: Log odds of positive lymph nodes.

Figure 2 Box plots of the log odds of positive lymph nodes according to clinical features. A: Age; B: Pathological type; C: Differentiation; D: Body mass index; E: Nerve invasion; F: Vascular tumor thrombus; G: Recurrence or metastasis; H: Pathological tumor-node-metastasis. ^aP < 0.05; ^bP < 0.01; ^cP < 0.005; ^dP < 0.001. LODDS: Log odds of positive lymph nodes; pTNM: Pathological tumor-node-metastasis; MGC: Mucinous gastric adenocarcinoma; NMGC: Non-mucinous gastric adenocarcinoma; BMI: Body mass index; ns: Not significant.

Figure 3 Scatterplot of the correlation of log odds of positive lymph nodes with tumor markers. A: Carbohydrate antigen (CA) 19-9; B: Carcinoembryonic antigen; C: CA242; D: CA72-4; E: CA125; F: Alpha-fetoprotein. LODDS: Log odds of positive lymph nodes; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein.

Figure 4 Construction of a nomogram model to predict the prognosis of gastric cancer patients based on log odds of positive lymph nodes, tumor differentiation, and other independent risk factors. A: Nomogram; B: Calibration curve of the nomogram; C: Receiver operating characteristic curves for the nomogram and pathological tumor-node-metastasis staging systems; D: Kaplan–Meier curve of overall survival for the high-risk and low-risk groups based on the nomogram; E: Decision curve analysis comparing the nomogram with the pathological tumor-node-metastasis staging system. (P < 0.005). LODDS: Log odds of positive lymph nodes; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; pTNM: Pathological tumor-node-metastasis; OS: Overall survival; ROC: Receiver operating characteristic; AUC: Area under the curve.